Fusion Pharmaceuticals Inc [NASDAQ: FUSN] jumped around 0.06 points on Thursday, while shares priced at $21.47 at the close of the session, up 0.28%.
Compared to the average trading volume of 1.86M shares, FUSN reached a trading volume of 3961472 in the most recent trading day, which is why market watchdogs consider the stock to be active.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
What do top market gurus say about Fusion Pharmaceuticals Inc [FUSN]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for FUSN shares is $20.95 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on FUSN stock is a recommendation set at 3.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Raymond James have made an estimate for Fusion Pharmaceuticals Inc shares, keeping their opinion on the stock as Strong Buy, with their previous recommendation back on December 27, 2023. While these analysts kept the previous recommendation, Oppenheimer raised their target price to Outperform. The new note on the price target was released on September 29, 2023, representing the official price target for Fusion Pharmaceuticals Inc stock. Previously, the target price had yet another raise to $13, while Raymond James analysts kept a Outperform rating on FUSN stock.
The Average True Range (ATR) for Fusion Pharmaceuticals Inc is set at 0.13, with the Price to Sales ratio for FUSN stock in the period of the last 12 months amounting to 895.21. The Price to Book ratio for the last quarter was 7.53, with the Price to Cash per share for the same quarter was set at 2.48.
How has FUSN stock performed recently?
Fusion Pharmaceuticals Inc [FUSN] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -0.23. With this latest performance, FUSN shares gained by 0.19% in over the last four-week period, additionally plugging by 352.95% over the last 6 months – not to mention a rise of 396.99% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for FUSN stock in for the last two-week period is set at 66.08, with the RSI for the last a single of trading hit 55.47, and the three-weeks RSI is set at 71.11 for Fusion Pharmaceuticals Inc [FUSN]. The present Moving Average for the last 50 days of trading for this stock 21.38, while it was recorded at 21.46 for the last single week of trading, and 10.24 for the last 200 days.
Fusion Pharmaceuticals Inc [FUSN]: Deeper insight into the fundamentals
Fusion Pharmaceuticals Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 10.64 and a Current Ratio set at 10.64.
Insider trade positions for Fusion Pharmaceuticals Inc [FUSN]
The top three institutional holders of FUSN stocks are: VANGUARD GROUP INC with ownership of 1.32 billion shares, which is approximately 8.4983%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $200.69 billion in FUSN stocks shares; and BERKSHIRE HATHAWAY INC, currently with $174.35 billion in FUSN stock with ownership which is approximately 5.8386%.
